CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label

21-Apr-2008 - CryoLife, Inc. announced that it has signed an exclusive three-year agreement with Minneapolis-based Medafor, Inc. Under terms of the agreement CryoLife will distribute Medafor's microporous polysaccharide hemostatic agent for use in cardiac and vascular surgery in the U.S. and for cardiac, ...

CryoLife Signs Distribution Agreement for Inclusion of BioGlue Surgical Adhesive in Hernia Repair Kit

Hernia repair is a commonly performed surgical procedures

19-Sep-2007 - CryoLife, Inc. announced that it has signed a distribution agreement allowing Proxy Biomedical Limited to include CryoLife's BioGlue(R) Surgical Adhesive into a hernia repair kit. In addition to BioGlue, the kit includes a surgical mesh from Proxy Biomedical's line of proprietary synthetic ...

CryoLife Awarded U. S. Patent for BioFoam

Potential Product Applications Include Battlefield Injuries, Internal Organ and Vascular Tissue Sealing, and Tissue Augmentation

18-Jun-2007 - CryoLife, Inc. announced that it has been awarded a patent by the U.S. Patent Office for BioFoam(R), a protein hydrogel foam for rapidly filling and sealing open wounds. Scientists at CryoLife invented and developed this product as a hemostatic agent and tissue and organ sealant. CryoLife is ...

CryoLife to Receive $2.25 Million to Settle Dispute

06-Oct-2006 - CryoLife, Inc. has settled an outstanding insurance coverage dispute for $2.25 million. The dispute involved losses stemming from amounts paid in 2005 by the Company. In resolving the dispute, no party admitted any liability. Steven G. Anderson, President and Chief Executive Officer stated, "We ...

CryoLife and The Magdi Yacoub Institute Sign Research Collaboration to Improve Xenografts for Human Transplantation

22-Jun-2005 - CryoLife, Inc. announced that CryoLife and The Magdi Yacoub Institute, at the Imperial College, London, UK, have entered into a three year research collaboration to develop methods to improve the utilization of unfixed xenografts (animal tissues) for human transplantation. A primary focus of the ...

CryoLife Announces First Implant of Cryopreserved Osteoarticular Allograft

25-Feb-2005 - CryoLife, Inc. announced that a patient received the first Cryopreserved osteoarticular (OA) allograft transplant for resurfacing articular cartilage in the knee. The OA allograft is a section of bone with overlying cartilage derived from the end of the femur, in this case from the femoral ...

FDA Renews Interim Agreement With Cryolife

20-Mar-2003 - CryoLife, Inc., a leading human tissue processing and medical device company, announced that the U.S. Food and Drug Administration (FDA) has again renewed its September 5, 2002 Interim Agreement with the Company. The renewal allows CryoLife to continue distributing non-valved cardiac and vascular ...